Showing 7641-7650 of 9914 results for "".
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of
- Hands On: Practical Tips for Diagnosing and Treating Chronic Hand Eczemahttps://practicaldermatology.com/news/hands-on-practical-tips-for-diagnosing-and-treating-chronic-hand-eczema/2475415/Despite its small body surface area involvement, chronic hand eczema (CHE) represents a significant dermatologic and socioeconomic burden. In a recent session on chronic hand eczema (CHE) Socity of Dermatology Physician Associates (SDPA) 2025 Summer Conference given by Adam Friedman, MD, FAAD, he
- ZORYVE Cream 0.15% Gets AAD Endorsement for Atopic Dermatitishttps://practicaldermatology.com/news/zoryve-cream-015-gets-aad-endorsement-for-atopic-dermatitis/2475411/The American Academy of Dermatology (AAD) has issued a strong recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adult patients with mild to moderate atopic dermatitis (AD), according to updated guidelines released June 26.
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- Analysis: No Added MACE Risk With Ustekinumab in Psoriasis and PsAhttps://practicaldermatology.com/news/analysis-no-added-mace-risk-with-ustekinumab-in-psoriasis-and-psa/2475231/New research suggests no difference in the risk of major adverse cardiovascular events (MACE) among patients with psoriasis (PsO) and psoriatic arthritis (PsA) initiating ustekinumab compared to adalimumab, etanercept, or secukinumab.
- Dupilumab Linked to Higher Psoriasis Risk in AD Patientshttps://practicaldermatology.com/news/dupilumab-linked-to-higher-psoriasis-risk-in-ad-patients/2475230/Patients with atopic dermatitis (AD) prescribed dupilumab face a higher risk of developing psoriasis compared to those receiving other systemic agents, according to a large retrospective cohort study in JAMA Dermatology.
- Midmark Announces First USAB Compliant Procedure Chairhttps://practicaldermatology.com/news/Midmark-Announces-First-USAB-Compliant-Procedure-Chair/2475173/Midmark Corp. announced the launch of the Midmark 631 procedure chair, which the company said is the first US Access Board (USAB) compliant procedure chair. In 2024, the U.S. Access Board issued a new standard establishing design criteria for examination and procedure chairs, as well
- GALDA Co-Director Explains Organization's Work and Impacthttps://practicaldermatology.com/news/GALDA-Co-Director-Explains-Organizations-Work-Impact/2475171/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- AB Chopra Epigenetics Launches With Plan to Revolutionize Longevityhttps://practicaldermatology.com/news/AB-Chopra-Epigenetics-Launches-With-Plan-Revolutionize-Longevity/2475124/Charles Rosier, co-founder of the Augustinus Bader skincare and biotech company, and Deepak Chopra, MD, announced the launch of AB Chopra Epigenetics, a revolutionary longevity platform that merges advanced artificial intelligence, epigenetic science, and consciousness-based healing to redefine t